Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

PALO ALTO, Calif., Sept. 5, 2023 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will…

Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks